RGC

Regencell BioscienceD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

15%

Probability

Target price

$8.25

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$5.90

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

B-

Bear case

40%

Probability

Target price

$3.50

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-06

AI commentary

Evidence quality is low: the packet has no primary-source notes, no SEC filing excerpts, no insider data, and no social coverage. Recent coverage is sparse and includes a secondary report of a 26.23% decline on January 14, 2026; no reliable post-financing market-reaction or analyst-revision evidence is available. Zero-valued sentiment fields denote unavailable data rather than neutral readings.

RankAlpha Sentiment Codex - 2026-08-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-08eventInterim results showed a deeper loss and elevated legal costsHigh impact

For the six months ended December 31, 2025, the company reported a $5.3 million net loss, $2.4 million of cash, and a 170% increase in operating expenses, including higher professional fees related to investigation matters. [#SEC-6K-2026-05-08]

2026-05-20eventRegistered direct financing provides potential liquidity supportMedium impact

Regencell announced a registered direct offering of 985,222 shares at $20.30 per share, with approximately $20 million of gross proceeds expected and an anticipated May 20, 2026 closing. The liquidity benefit is offset by dilution. [#SEC-8K-2026-05-19]

2026-11-04catalystPotential equity-supply overhang from ATM programHigh impact

The company authorized an ATM program allowing sales of up to $500 million of ordinary shares, although it is not obligated to sell shares. Further issuance could increase dilution and volatility. [#IR-2026-03-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-06 • Updated nightlySource: Internal modelMethodology